drugset / Trial / NCT02446353

Pharmacokinetics and Safety Study of Apetrol ES

NCT02446353

Phase 1 Completed 79 enrolled LG Life Sciences Severance Hospital · collab
RandomizedCrossoverOpen-labelTreatment

Summary

A Randomized, Open Label, Single dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of Apetrol ES and Megace® in Healthy Male Volunteers.

Timeline

Start
2010-04
Primary completion
2010-06
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Megestrol Acetate Other / unclassified 625 mg
Subject Megestrol Acetate Other / unclassified 800 mg

Indications

No indication recorded.